Amber TongSenior Editor The ballooning controversy around Biogen and its Alzheimer’s drug isn’t deterring others from the gold rush — and the search is global. China’s Simcere is licensing regional rights to a Phase IIb anti-amyloid drug from German biotech Vivoryon Therapeutics and taking the lead on clinical development locally. All told, the pact is...